跳至主要内容
临床试验/NCT00928070
NCT00928070已完成4 期

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.

Pfizer1 个研究点 分布在 1 个国家目标入组 566 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Pfizer
入组人数
566
试验地点
1
主要终点
Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours

研究概览

简要总结

This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female subjects 65 years of age or older
  • OAB symptoms for at least 3 months
  • score 3 or greater on Vulnerable Elderly Survey (VES-13)
  • adequate mobility for independent toileting
  • mean number of at least 2 UUI episodes per 24 hours
  • mean urinary frequency of 8 or more micturitions per 24 hours
  • able to independently complete the bladder diaries

排除标准

  • PVR urinary volume greater than 200 ml
  • MMSE score less than 20
  • greater than 15 UUI episodes per 24 hours
  • creatinine clearance less than 30 ml/min
  • an average resting heart rate of greater than or equal to 90 beats per minute

研究组 & 干预措施

Fesoterodine

Experimental

干预措施: Fesoterodine (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours

时间窗: Baseline

UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12

时间窗: Baseline, Week 12

UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

次要结局

  • Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4(Baseline, Week 4)
  • Percent Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Mean Number of Micturitions Per 24 Hours(Baseline)
  • Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Percent Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Mean Number of Micturition-related Urgency Episodes Per 24 Hours(Baseline)
  • Change From Baseline in Mean Number of Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Percent Change From Baseline in Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours(Baseline)
  • Change From Baseline in Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Percent Change From Baseline in Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Frequency-Urgency Sum Rating Per 24 Hours(Baseline)
  • Change From Baseline in Frequency-Urgency Sum Rating Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Change From Baseline in Mean Number of Protective Undergarments Changed Due to Urinary Leakage Per 24 Hours at Week 4 and 12(Baseline, Week 4, 12)
  • Percentage of Participants With Change From Screening in Patient Perception of Bladder Condition (PPBC) at Week 4 and 12(Screening, Week 4, 12)
  • Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score(Baseline)
  • Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 4 and 12(Baseline, Week 4, 12)
  • Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q)(Baseline)
  • Change From Baseline in Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 4 and 12(Baseline, Week 4, 12)
  • Overactive Bladder Satisfaction Questionnaire (OAB-S) Total Score on Satisfaction With OAB Control(Week 12)
  • Percentage of Participants With Overactive Bladder Satisfaction Questionnaire (OAB-S) Global Medication Satisfaction Question Response(Week 12)
  • Mini Mental State Examination (MMSE)(Screening)
  • Change From Screening in Mini Mental State Examination (MMSE) Score at Week 12(Screening, Week 12)
  • Change From Baseline in Post Void Residual (PVR) Volume at Week 4 and 12(Baseline, Week 4, 12)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Study Of Efficacy And Safety Of Fesoterodine In... | 临床试验